BIIB068

Overview

BIIB068 is a potent, selective, reversible and orally active BTK inhibitor with an IC 50 of 1 nM and a K d of 0.3 nM. BIIB068 shows more >400-fold selective for BTK than other kinases. BIIB068 has the potential for autoimmune diseases research.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-131342
• CAS No.: 1798787-27-5
• Molecular Formula: C23H29N7O2
• Molecular Weight: 435.52
• Purity: 98.35%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.78 mM); Clear solution
• Availability: In-stock

Source

Original product source